Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06450210 · ClinicalTrials.gov registry record · Phase 1
Safety for Home Administration of Microdose Psilocybin Use
A Phase 1 study of Psychedelic Experiences, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06450210 is a Phase 1 study of Psychedelic Experiences that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 20 participants, below the 36-participant average among 4 other Psychedelic Experiences trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06450210, a Phase 1 study of Psychedelic Experiences, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this laboratory study is to establish whether and which microdoses of psilocybin are safe to administer at home to healthy participants. Eligible participants will be given ascending doses of psilocybin trihydrate and a single, interspersed, randomized placebo on separate days in double-blind fashion. The participants will be asked to complete questionnaires and undergo safety assessments.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG psilocybin trihydrate
Study Locations (1)
Maryland
- 5510 Nathan Shock Drive - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-12-06 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06450210
The ClinicalTrials.gov registry entry for NCT06450210 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36-participant average among 4 other Psychedelic Experiences trials with a reported enrollment target (44% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psychedelic Experiences appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06450210 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06450210 about?
NCT06450210 is a clinical study titled "Safety for Home Administration of Microdose Psilocybin Use". The goal of this laboratory study is to establish whether and which microdoses of psilocybin are safe to administer at home to healthy participants. Eligible participants will be given ascending doses of psilocybin trihydrate and a single, interspersed, randomized placebo on separate days in double...
What is the current status of trial NCT06450210?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-12-06. Estimated completion is 2027-07.
What conditions does trial NCT06450210 study?
This clinical trial studies the following conditions: Psychedelic Experiences.
What interventions are being tested in trial NCT06450210?
The interventions under investigation include: Placebo (DRUG), psilocybin trihydrate (DRUG).
Who is sponsoring clinical trial NCT06450210?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06450210 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psychedelic Experiences
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.